GeneDx Holdings Corp.
GeneDx develops and provides genomic testing and interpretation services for patients, clinicians and healthcare partners, with a focus on rare and ultra-rare genetic disorders. Its products include ExomeDx and GenomeDx tests, standard and rapid genome sequencing, prenatal exome testing and genomic newborn screening protocols. The company also offers data and information services, including genomic interpretation capabilities, and works with biopharmaceutical companies on data and research solutions. GeneDx receives payments from third-party payors, patients, business-to-business clients and other healthcare partners, with diagnostic test reports currently accounting for substantially all of its revenue. GeneDx’s GeneDx Infinity dataset combines genomic test results with phenotypic and longitudinal patient data and supports clinical interpretation and discovery. Its operations include a clinical laboratory in Gaithersburg, Maryland. GeneDx is headquartered in Stamford, Connecticut.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $WGS in the last 30 days.
See all $WGS insider activity →ARK ETFs sold $49.2M in SpaceX shares, bought $9M in Nurix Therapeutics. Also sold Alphabet and Eli Lilly, bought Twist Bioscience and Pacific Biosciences. Transactions reflect ARK's strategic shifts in tech and biotech sectors.
GeneDx (WGS) reported negative cash flow in three of the last four quarters, burning $39.1M in Q2 2026. Its cash reserves may last 3-7 quarters at current burn rates. The company increased debt to $167M and share count by 11.6% since 2024. Management expects improved collections and cash generation by 2027.
GeneDx (Nasdaq: WGS) announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). This technology identifies complex genetic variations undetectable by traditional methods. The company aims to offer lrWGS upfront for eligible patients, reducing sequential testing and accelerating diagnosis. GeneDx's approach combines advanced sequencing, phenotypic data, and clinical expertise to deliver meaningful answers for rare disease patients.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning WGS (GeneDx Holdings Corp.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent WGS coverage spans insider activity, financial news and market movers.
Potential modest upside.
GeneDx (WGS) reported negative cash flow in three of the last four quarters, burning $39.1M in Q2 2026. Its cash reserves may last 3-7 quarters at current burn rates. The company increased debt to $167M and share count by 11.6% since 2024. Management expects improved collections and cash generation by 2027.
Potential upside for GeneDx as it expands its testing portfolio, but impact depends on adoption and reimbursement.
The program could boost test volumes and data assets but may pressure margins due to low per‑case revenue.
Minor bearish indication.
AlphAI scores every news story that mentions WGS with an AI model for sentiment and relevance, and aggregates insider trades from GeneDx Holdings Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ARK ETFs sold $49.2M in SpaceX shares, bought $9M in Nurix Therapeutics. Also sold Alphabet and Eli Lilly, bought Twist Bioscience and Pacific Biosciences. Transactions reflect ARK's strategic shifts in tech and biotech sectors.
GeneDx (WGS) reported negative cash flow in three of the last four quarters, burning $39.1M in Q2 2026. Its cash reserves may last 3-7 quarters at current burn rates. The company increased debt to $167M and share count by 11.6% since 2024. Management expects improved collections and cash generation by 2027.
GeneDx (Nasdaq: WGS) announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). This technology identifies complex genetic variations undetectable by traditional methods. The company aims to offer lrWGS upfront for eligible patients, reducing sequential testing and accelerating diagnosis. GeneDx's approach combines advanced sequencing, phenotypic data, and clinical expertise to deliver meaningful answers for rare disease patients.
GeneDx (WGS) and Beren Therapeutics launched the NPC GenomeComplete program, offering free genome sequencing for children with suspected Niemann-Pick Disease Type C. The initiative aims to expand GeneDx's pediatric rare disease testing and includes rapid 48-hour sequencing. Analysts project $795.6M revenue and $29.2M earnings for GeneDx by 2029, with concerns about commoditization and pricing pressure.
Cathie Wood's Ark Invest sold crypto-linked positions including ARK 21Shares Bitcoin ETF (ARKB), Coinbase (COIN), and Circle Internet Group (CRCL) on Monday, then bought CoreWeave (CRWV) shares on Thursday after the company announced new contracts and a funding plan. CRWV stock fell 4% this week. Other notable trades included AeroVironment (AVAV) and Meta Platforms (META).
Stueland Katherine (CHIEF EXECUTIVE OFFICER) sold 10,501 shares of GeneDx Holdings Corp. (WGS) at an average of $97.61 ($94.26–$99.00, $1.03M total) across 5 trades on 2026-09-16.
Feeley Kevin (CHIEF FINANCIAL OFFICER) sold 3,728 shares of GeneDx Holdings Corp. (WGS) at an average of $97.61 ($94.26–$99.00, $0.36M total) across 5 trades on 2026-09-16.
ARK Invest, led by Cathie Wood, sold shares in multiple crypto-linked holdings, including ARKB, COIN, CRCL, and BMNR. The firm trimmed over 1.5% of its Bitcoin ETF (ARKB) positions. Bitcoin's price fell below $77,000, and retail sentiment remained bearish. Other tech stocks like AMZN, AMD, and SHOP were also reduced.
Stueland Katherine (CHIEF EXECUTIVE OFFICER) sold 3,692 shares of GeneDx Holdings Corp. (WGS) at $84.22 ($0.31M total) on 2026-09-09.
Feeley Kevin (CHIEF FINANCIAL OFFICER) sold 1,285 shares of GeneDx Holdings Corp. (WGS) at $84.22 ($0.11M total) on 2026-09-09.
